Second, we built a culture that values impact over broad activity. As AI increasingly handles routine tasks that once ...

Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E. Click here to read more about SNY stock and why it ...

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

Shares of Nurix Therapeutics jumped on Wednesday after the biotech company reported stronger-than-expected results for the ...

Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a third program and agreeing to sponsor a trial of its partner’s lead candidate.

Sanofi wins ‘Top GCC of 2025’ and ‘GCC Country Leader of the Year’ at Zyoin Group workplace summit and awards 2025: Our Bureau, Bengaluru Monday, July 14, 2025, 15:30 Hrs ...

In Japan alone, around 4,000 individuals have a CIDP diagnosis. Sanofi neurology development global head Erik Wallstroem stated: “The orphan drug designation of riliprubart for ...

Transplants can be life-saving – but for many, the journey doesn’t end there. Up to 40% of people receiving a stem cell or bone marrow transplant will go on to develop a serious complication known as ...

Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Sanofi on July 10 and set a price target of €95.00. The company’s shares closed yesterday at $98.70. Elevat ...